Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma

Trial Details

NCT ID

NCT05524935

Phase

PHASE2

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Status

RECRUITING

Cancer Type

Melanoma

Locations (sample)

• Tampa, Florida, United States|27.94752,-82.45843

Key Eligibility Criteria

• Male or female participants who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of meta…
• Male participants: A male participant must agree to use a contraception as detailed in Appendix 3 of this protocol during the treatment period and …
• Female participants: A female participant is eligible to participate if she is not pregnant (see Appendix 3), not breastfeeding, and at least one o…
• The participant (or legally acceptable representative if applicable) provides written informed consent for the trial.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.